R&D | January 06, 2026
Insilico Medicine teams up with Servier to fast-track AI-driven cancer drugs
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
Elanco expects Befrena to launch in the US in the first half of 2026
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
The partnership also sets the stage for broader collaboration on rare disease treatments
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
Subscribe To Our Newsletter & Stay Updated
